Disease control in advanced Hodgkin lymphoma
15 Jun 2018
Disease control in advanced Hodgkin lymphoma
Improved OS with obinutuzumab in the CLL11 study
Minimised BEACOPP exposure and toxicity for Hodgkin lymphoma gives good results
Mapping 3D genome dynamics in B cells
Update on bb2121 for relapsed myeloma
Repurposing selective PDE5 inhibitors as anti-cancer agents
First results of DREAM trial of frontline durvalumab for mesothelioma
Results from the phase I ICONIC trial
Phase II results of olaparib and abiraterone for mCRPC
Global treatment pattern variations in HCC
Design and interim safety analysis of GeparX trial
International cancer control plans